Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Accumulated Expenses: 2012-2025

Historic Other Accumulated Expenses for Enanta Pharmaceuticals (ENTA) over the last 11 years, with Sep 2025 value amounting to $1.8 million.

  • Enanta Pharmaceuticals' Other Accumulated Expenses fell 41.69% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 41.69%. This contributed to the annual value of $1.8 million for FY2025, which is 41.69% down from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' Other Accumulated Expenses stood at $1.8 million, which was down 26.47% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Other Accumulated Expenses registered a high of $14.4 million during Q1 2022, and its lowest value of $1.5 million during Q1 2024.
  • For the 3-year period, Enanta Pharmaceuticals' Other Accumulated Expenses averaged around $3.4 million, with its median value being $3.0 million (2024).
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Other Accumulated Expenses soared by 144.13% in 2021, and later plummeted by 71.58% in 2024.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Other Accumulated Expenses stood at $6.4 million in 2021, then climbed by 6.44% to $6.9 million in 2022, then tumbled by 45.98% to $3.7 million in 2023, then fell by 18.64% to $3.0 million in 2024, then plummeted by 41.69% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, $2.4 million for Q2 2025, and $1.6 million during Q1 2025.